HIV-fertőzés: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CCR5 1
• CXCR4 0
• PD-1 2
• IL-15 1
• JAK 1
• STING 0
• GLP-1 2
• IL-17 0
• PD-L1 1
• TNF 0
• IL-6 0
• mTOR 1
• TP53 0
• NLRP3 0
• SGLT2 2
• STAT3 0
• AKT 0
• APOL1 0
• PCSK9 0
• PPAR 0
• CD40 1
• NRF2 0
• PI3K 0
• BCL-2 2
• CD19 1
• ERK 0
• HDAC 0
• HIF-1 0
• APOE 0
• BRD4 0
• FOXP3 0
• HSP90 0
• MAPK 0
• METTL3 0
• AMPK 0
• ATM 0
• BDNF 0
• CD20 0
• CD38 0
• CTNNB1 0
• FLT3 0
• HMGB1 0
• IL-1 0
• MET 0
• NMDA 0
• TIGIT 0
• VEGF 0
• ACE2 0
• ALK 0
• ANGPTL3 0
• AQP4 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CFTR 0
• COX-2 0
• CTLA-4 0
• DPP-4 0
• FTO 0
• G6PD 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F30

  Development and Implementation of a Cost-Effective Diagnostic Algorithm to Reduce AIDS-Related Deaths among Hospitalized People with Advanced HIV Disease

  University of Minnesota· Minneapolis, Egyesült Államok· 55 114 USD awarded in fiscal year 2026· until 2030. okt.

• NIH NIAID · F32

  ENV GLYCOPROTEIN INCORPORATION AT HIV-1 ASSEMBLY SITES: STERIC REGULATION DRIVEN BY THE LONG CYTOPLASMIC TAIL

  University of Denver (Colorado Seminary)· Denver, Egyesült Államok· 89 476 USD awarded in fiscal year 2026· until 2027. okt.

• NIH NIAID · F31

  Human retrovirus assembly interplay with the actin cortex

  University of Minnesota· Minneapolis, Egyesült Államok· 48 621 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NIDA · K24

  Mentoring in community-engaged research to address HIV and substance use

  Emory University· Atlanta, Egyesült Államok· 217 483 USD awarded in fiscal year 2026· until 2031. aug.

• NIH OD · N01

  Prototype Pediatric Oral Dissolving Films for the Prevention of Tuberculosis (TB)

  Advanced Bioscience Laboratories, Inc.· Rockville, Egyesült Államok· 2 559 631 USD awarded in fiscal year 2026· until 2028. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Comparative and entangled histories of AIDS care in Austria and Slovenia, 1980s–2000s (AIDScare)

  Universitaet Graz· Graz, Ausztria· EU contribution 230 185 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Immunometabolic Reprogramming via a Gut-derived Organoid Platform (IRGOP)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2028. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  BRIDGING RESERVOIR SCIENCE, INTEGRATED DRUG DISCOVERY, BIG DATA ANALYTICS, ARTIFICIAL INTELLIGENCE AND EPIDEMIOLOGY (BRIDGE-HIV)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Hollandia· EU contribution 1 703 400 EUR· until 2030. szept.· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-CSA

  West African Network of Excellence for TB, AIDS and Malaria (WANETAM-4)

  European & Developing Countries Clinical Trials Partnership· Den Haag, Hollandia· EU contribution 12 751 885 EUR· until 2031. jún.· 14 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Defining the Landscape of Transcriptional Activity during HIV-1 Infection (DELTA-HIV)

  King's College London· London, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. máj.

10 of 2889 running projects, newest first. Listed amounts together: 2,2 Mrd USD + 81,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Immunotherapy with a JAK1/JAK2 inhibitor (baricitinib) and an mTORC1 inhibitor (sirolimus), alone and in combination, for the control of HIV-1 replication after antiretroviral treatment interruption: a phase II multicenter, multi-arm, multi-stage, randomized, double-blind, placebo-controlled, adaptative trial

  NCT07081763· ANRS Maladies Infectieuses Emergentes· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 22
• Organoids 6
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 27
• Gene Expression Profiling 62
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 15
• Exome Sequencing 3
• Proteomics 37
• Metabolomics 33
• Mass Spectrometry 16
• Flow Cytometry 45
• Immunohistochemistry 15
• Xenograft Model Antitumor Assays 3
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 79
• Machine Learning 72
• Deep Learning 21
• Cohort Studies 426
• Genome-Wide Association Study 20

• Integrating Omics to Advance Antiretroviral Pharmacology in Pregnancy: Dolutegravir-Based Regimens as a Case Study.

  J Clin Pharmacol, 2026. nov.

• Cross-omics mapping of the human HIV restrictome across clinical states, immune-cell compartments, and protein responses.

  PLoS One, 2026. okt.

• Integrated proteomics and metabolomics for predicting cardiometabolic risk in pregnant women living with HIV: current evidence and future directions.

  Expert Rev Mol Diagn, 2026. okt.

• Distinct inflammatory marker profiles of adolescents and young adults among the HIV risk, infection, and treatment spectrum.

  Nat Commun, 2026. szept.

• Unsupervised proteomic stratification of people living with HIV reveals inflammatory biotypes beyond conventional clinical classifications.

  Front Immunol, 2026. szept.

• Tissue origins and immune correlates of viral rebound in SIV-infected rhesus macaques after ART discontinuation.

  Sci Transl Med, 2026. szept.

• Proteomic Immune Signatures of Severe HIV-Associated Tuberculosis in Sub-Saharan Africa: A Prospective, Multicenter Analysis From Uganda.

  Crit Care Explor, 2026. aug.

• Multiomics profiling of plasma reveals lipid-immune dysregulation and exosome remodeling in mpox and mpox-HIV co-infection.

  Med, 2026. aug.

• Approximating Molecular Sepsis Subtypes Using Bedside Data in Resource-Limited Settings: A Multicenter Analysis From Uganda.

  Crit Care Explor, 2026. aug.

• Elucidating the mechanism underlying incomplete immune recovery in people living with HIV through CD4⁺ and CD8⁺ T cell multi-omics.

  Mol Med, 2026. aug.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.